Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Update

Autonomix Medical, Inc. (NASDAQ:AMIX) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,543,188 shares, an increase of 1,052.8% from the December 15th total of 133,864 shares. Based on an average daily volume of 12,719,755 shares, the short-interest ratio is presently 0.1 days. Currently, 23.8% of the company’s stock are short sold. Currently, 23.8% of the company’s stock are short sold. Based on an average daily volume of 12,719,755 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Autonomix Medical in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Autonomix Medical currently has an average rating of “Hold” and an average price target of $5.00.

Autonomix Medical Price Performance

Shares of AMIX stock traded down $0.01 during trading hours on Monday, hitting $0.51. The stock had a trading volume of 1,691,812 shares, compared to its average volume of 9,488,779. Autonomix Medical has a twelve month low of $0.47 and a twelve month high of $3.33. The stock’s 50 day moving average is $0.76 and its 200 day moving average is $1.06.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Wednesday, November 12th. The company reported ($1.38) earnings per share for the quarter, hitting the consensus estimate of ($1.38). As a group, equities analysts anticipate that Autonomix Medical will post -10 EPS for the current year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.